Skip to content

Short Term Cardiovascular Effects and Oxidative Status of Calcium and Vitamin D Supplementation of Postmenopausal Hypertensive Blacks Women

Short Term Cardiovascular Effects and Oxidative Status of Calcium and Vitamin D Supplementation of Postmenopausal Hypertensive Blacks Women in Sub Saharan Africa

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04255992
Enrollment
22
Registered
2020-02-05
Start date
2018-11-01
Completion date
2019-05-15
Last updated
2020-02-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension, Postmenopausal Disorder

Keywords

Blood pressure, Oxidative status

Brief summary

This study aims to determine the effect of calcium and vitamin D supplementation on oxidative status and blood pressure profile of postmenopausal patients with high blood pressure in Yaoundé, Cameroon. This study is a double-arm, double-blind, randomized and parallel clinical trial conducted at the Yaoundé Central Hospital

Detailed description

Aim: to determine and compare the short term effect of calcium and vitamin D supplementation on oxidative status and blood pressure profile of postmenopausal patients with high blood pressure in Yaoundé, Cameroon. Method: A double-arm, double-blind, randomized and parallel clinical trial conducted at the Yaoundé Central Hospital. Postmenopausal hypertensive blacks women who are taking taking antihypertensives drugs since 12 months,without diabetes mellitus or any inflammatory disease or hypercalcemia, are randomize into 2 groups. Depending on the group, the intervention consisted of the administration of Calcium 1000 mg daily or Vitamin D/Calcium 1000 mg/800 UI daily for 08 weeks. The endpoints were the nycthemeral blood pressure profile, pro oxidant marker (malondialdehyde) and anti-oxidant marker (Ferric reducing antioxidant). Progress: Recruitment for this study was completed in May 2019 with 22 patients.

Interventions

DIETARY_SUPPLEMENTCalcium Arm

1000 mg Calcium tablet / day will be added to the usual treatment for each patient for a period of 8 weeks.

DIETARY_SUPPLEMENTVitamin D/Calcium

1000 mg/800UI of the association Vitamin D/Calcium tablet / day will be added to the usual treatment for each patient for a period of 8 weeks.

Sponsors

Yaounde Central Hospital
Lead SponsorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Masking description

The double-blind model is applied to the study. Only the adjudicator, responsible for the distribution of medication knew the different regimes. Calcium and Vitamin D/Calcium were packaged in boxes of identical appearance and labeled for each participant by name and number of the randomization program. The randomization and packaging of the drugs was done by an investigator who had no clinical involvement.

Intervention model description

This study is a double blind, randomized, controlled parallel clinical trial conducted at the Yaounde central hospital, Cameroon

Eligibility

Sex/Gender
FEMALE
Age
30 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

* Post menopausal hypertensive women since 12 months * On a stable antihypertensive therapies (determined by the investigator) for at least 3 months with no classes changes. * Before any study-specific procedure, the appropriate written informed consent must be obtained.

Exclusion criteria

* Diabetes mellitus or inflammatory diseases * Hypercalcemia, * Side effects affecting life quality of patients (determined by the Data Safety Monitoring Board). * Withdrawal of consent

Design outcomes

Primary

MeasureTime frameDescription
Change in nycthemeral blood pressure profile (mmHg)8 weeksChange in nycthemeral blood pressure profile from baseline to week 08. By using Arterial Blood Pressure Monitoring.

Secondary

MeasureTime frameDescription
Change in serum concentration of oxidant marker: malondialdehyde (micromol/l)8 weeksChange in concentration of oxidant marker from baseline to week 8. By spectrophotometer

Other

MeasureTime frameDescription
Change in serum concentration of anti-oxidant markers: Ferric reducing antioxidant Power (micromol)8 weeksChange in concentration of anti oxidant marker from baseline to week 8. By spectrophotometer

Countries

Cameroon

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026